Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06497517 | A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants | PHASE1 | COMPLETED | 14 | — | — | Jul 9, 2024 | Aug 26, 2024 | Feb 7, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | In sequence 1, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 under fasting condition (Treatment A), followed by single dose of GSK5464714 in fed condition (Treatment B). There will be a washout period of minimum 7 days between each period. |
| Sequence 2 | EXPERIMENTAL | In sequence 2, eligible participants will be randomly assigned to 1 of 2 sequences to receive single dose of GSK5464714- Camlipixant on Day 1 in fed condition (Treatment B), followed by single dose of GSK5464714 under fasting condition (Treatment A). There will be a washout period of minimum 7 days between each period. |
| Name | Type | Description |
|---|---|---|
| GSK5464714- Camlipixant | DRUG | GSK5464714- Camlipixant will be administered |
Inclusion Criteria: * Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, clinical laboratory tests, vital sign measurements, and 12-lead ECGs including the following: * Seat...